Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia

Summary

There is no in vitro data on the comparison of the effects of danaparoid, argatroban and fondaparinux on thrombin generation in patients with heparin-induced thrombocytopenia. It was the study objective to compare the in vitro anticoagulant potential of argatroban, danaparoid and fondaparinux using a thrombin generation assay TGA on a mixture of control platelet-rich plasma (PRP) and HIT patient platelet-poor plasma (PPP). The plasma of seven patients with a clear HIT diagnosed at our institution was selected. Mixtures of donor PRP and patient PPP were incubated with unfractionated heparin 0.2 U.mL^-1, argatroban at 600 ng.mL^-1, argatroban at 400 ng.mL^-1, danaparoid at 0.65 IU.mL^-1 and fondaparinux at 1 [uni03BC]g.mL^-1. Thrombin generation was assessed by calibrated thrombinography. The percentage of inhibition of the endogenous thrombin potential observed with argatroban at 600 ng.mL^-1 was statistically significantly higher compared with those observed with fondaparinux (median: 53.6% vs. 3.9%; p = 0.031) but not compared with argatroban at 400 ng.mL^-1 and danaparoid. The percentage of inhibition of the thrombin peak observed with argatroban at 600 ng.mL^-1 was statistically significantly higher compared with those observed with danaparoid (median: 71.2 vs. 56.8; p = 0.031) and fondaparinux (mean: 71.2 vs. 30; p = 0.031) but not with argatroban at 400 ng.mL^-1. In conclusion, the in vitro effect of argatroban and danaparoid on thrombin generation seems to corroborate the results of clinical studies of these drugs in the treatment of HIT in term of efficiency. Fondaparinux showed a very small effect on thrombin generation evaluated by calibrated thrombinography.

Keywords

Heparin-induced thrombocytopenia - thrombin generation - direct thrombin inhibitor - danaparoid - fondaparinux

• References

• 1 Baglin TP. Heparin induced thrombocytopenia thrombosis (HIT/T) syndrome: diagnosis and treatment. J Clin Pathol 2001; 54: 272-274
• 2 Reilly RF. The pathophysiology of immune-mediated heparin-induced thrombocytopenia. Semin Dial 2003; 16: 54-60.
• 3 Amiral J, Bridey F, Dreyfus M. et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992; 68: 95-96.
• 4 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
• 5 Warkentin TE, Kelton JG. A 14-year study of heparin induced thrombocytopenia. Am J Med 1996; 101: 502-507.
• 6 Warkentin TE, Hayward CP, Boshkov LK. et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84: 3691-3699.
• 7 Tardy-Poncet B, Piot M, Chapelle C. et al. Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7: 1474-1481.
• 8 Hemker HC, Giesen P, AlDieri R. et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-253.
• 9 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
• 10 Robert S, Ghiotto J, Pirotte B. et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. Pharmacol Res 2009; 59: 160-166.
• 11 Petros S, Siegemund T, Siegemund A, Engelmann L. The effect of different anticoagulants on thrombin generation. Blood Coagul Fibrinolysis 2006; 17: 131-137.
• 12 Samama MM, Le Flem L, Guinet C. et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5: 2554-2556.
• 13 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008; 133: 340S-380S.
• 14 Warkentin TE, Pai M, Sheppard J. et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16 patient-case series. J Thromb Haemost 2011; 9: 2389-2396.
• 15 Goldfarb MJ, Blostein M. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost 2011; 9: 2501-2503.
• 16 Beilfu A, Grandoch M, Wenzel F. et al. Differential effects of factor IIa inhibitors on the endogenous thrombin potential. Ther Drug Monit 2008; 30: 740-743.
• 17 Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-157
• 18 Pouplard C, Amiral J, Borg JY. et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol 1997; 99: 273-280.
• 19 Hirsh J, Bauer KA, Donatti B. et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Bases Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 141S-159S.
• 20 Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Bases Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 340S-380S.
• 21 Hemker HC, Giesen PL, Ramjee M. et al. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-591.
• 22 Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344-350.
• 23 Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia with fondaparinux. Thromb Haemost 2005; 93: 999-1000.
• 24 Lobo B, Finch C, Howard A. et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
• 25 Grouzi E, Kyriakou E, Panagou I. et al. Fondaparinux for the treatment of acute heparin induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost 2010; 16: 663-667.
• 26 Pappalardo F, Scandroglio A, Maj G. et al. Treatment of heparin induced thrombocytopenia after cardiac surgery: preliminary experience with fondaparinux. J Thorac Cardiovasc Surg 2010; 139: 790-792.
• 27 Al Dieri R, Alban S, Béguin S. et al. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2: 1395-1401.
• 28 Farner B, Eichler P, Kroll H. et al. A comparison of danaparoid and lepirudin in Heparin induced thrombocytopenia. Thromb Haemost 2001; 85: 950-957.
• 29 Greinacher A. Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost 2011; 9: 2386-2388.
• 30 Maurer SH, Williams JA, Wang WC, Reiss UM. Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. Pediatr Blood Cancer 2009; 53: 468-471.
• 31 Miranda AC, Donovan JL, Tran MT. et al. A case of unsuccessful of heparin induced thrombocytopenia with fondaparinux. J Thromb Thrombolysis 2012; 33: 133-135.